Detail akcie ARYx Thera online

Business Summary: ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2010, ARYx Therapeutics, Inc. revenues was not reported. Net loss decreased 54% to $12.5M. Lower net loss reflects Research and development decrease of 77% to $4.1M (expense), Interest expense decrease of 21% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.00 to -$0.39.